But the efficacy rate of 70% that Sinopharm announced publicly in December wasthan the efficacy rate for a jab that the UAE had announced just weeks earlier.
When news agency Reuters asked if Sinopharm could explain the varying results, a spokesperson for the company declined to comment.Meanwhile, Russian scientists from the Gamaleya National Center of Epidemiology and MicrobiologyBut, despite promises by Gamaleya then, it hasn’t published peer-reviewed findings from late-stage Covid-19 vaccine trials — nor have Sinopharm and Sinovac.
Early published results from Sputnik trials drew sharp criticism from a consortium of international scientists who, writing inin the data. Russian researchers denied this and offered to share their data with the group. Concerns around missing data for some or all of these vaccines have been cited by health departments or regulators in South Africa andUntil more published data is available from large, late-stage clinical trials on Chinese and Russian vaccines, many more regulators are likely to be unwilling to register the jabs for use in countries. It may also make it more difficult for the African Union to include these vaccines in its pooled procurement efforts.
South African president and AU chairperson Cyril Ramaphosa has suggested that China will eventually be part of the AU’s efforts to supplement vaccines obtained through the World Health Organisation’s Covax facility. Covax aims to pool countries’ purchasing power to secure affordable vaccines for all participating countries.
A great Leader
Cyril RamaUselss, Loser of South Africa, do you see that ?CyrilRamaphosa
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.